NEW YORK, April 27, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the details of two poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Conference, taking place May 1-5, 2016 at the Washington State Convention Center in Seattle, Washington.
|Title:||Sustained Retinal Concentrations of OHR3031 Achieved with Intravitreal Injection of a Biodegradable Microparticle Formulation to Rabbits|
|Authors:||Modi M, Wirostko W, Jennings R, Reddy L, Malavia N, Simonian A, Szinai I, Stoller G|
|Date:||Sunday, May 1, 2016|
|Time:||1:30pm to 3:15pm Pacific Time|
|Title:||CNV lesion characteristics as a predictor of visual outcome in wet AMD patients receiving combination therapy of intravitreal anti-VEGF therapy and topical Squalamine lactate ophthalmic solution|
|Authors:||Brown D, Ingerman A, Shearn S, Slakter J|
|Date:||Wednesday, May 4, 2016|
|Time:||8:30am to 10:15am Pacific Time|
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, squalamine lactate ophthalmic solution, 0.2% (“Squalamine,” also known as OHR-102), is currently being studied using an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Source:Ohr Pharmaceutical, Inc.